



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

CD69 Monoclonal Antibody [BLR170J]

Rabbit Recombinant Monoclonal

Purified RefSeq ID NP_001772.1
Catalog No. A700-170CF Uniprot ID Q07108
Lot No. A700-170CF-1

SPECIES REACTIVITY	Human
AMOUNT	100 µl
CONCENTRATION	1000 µg/ml
STORAGE/SHELF LIFE	2 – 8°C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Borate Buffered Saline (BBS) pH 8.2 with 0.09% Sodium Azide, BSA Free
ISOTYPE	IgG
CLONE #	BLR170J
ORIGIN	USA
PRODUCTION PROCEDURES	Recombinant antibody was purified from cell culture supernatant. Immunogen was a recombinant protein representing the extracellular domain of human CD69 (residues 64–199, NP_001772.1).
APPLICATIONS	Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use. A700-170CF is the carrier-free version of A700-170, which is qualified for use in Western Blot, Immunoprecipitation, Immunohistochemistry, and/or Immunocytochemistry. The format of A700-170CF is designed for compatibility with the labeling of the antibody such as with fluorochromes, metal isotopes, oligonucleotides, and enzymes. Upon completion of labeling, the user must empirically define the assay dependent concentration for use.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Michael Spencer, PhD Date: September 29, 2022